Supernus Q1 revenue $207.7M (+39% YoY); growth products up 56%; reaffirms FY2026 guidance

SUPERNUS PHARMACEUTICALS, INC.

2026-Q1 EPS reported -$0.04 revenue$207,705,000

Total revenues $207.7M, up 39% YoY; combined growth product revenues $149.1M (+56%).
Qelbree net sales $77.9M (+20%), GOCOVRI $35.2M (+15%), ONAPGO $8.4M, ZURZUVAE collab revenue $27.6M (U.S. sales doubled per Biogen).
ONAPGO second supplier FDA submission expected Q3 2026; potential approval mid-2027.
Pipeline: SPN-817 (epilepsy) Phase 2b enrolling; SPN-820 (MDD) Phase 2b ongoing; SPN-443 (ADHD) Phase 1 expected H2 2026.
Company reiterates full year 2026 financial guidance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SUPERNUS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2026 results: revenue $207.7 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: $207.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Supernus Announces First Quarter 2026 Financial Results • Total revenues were $207.7 million in the first quarter 2026

View on SEC.gov

Browse all earnings releases →

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001356576-26-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.